Articles by Louis Garguilo

41. How Smaller Sponsors Can Compete For Attention At CDMOs 3/1/2019

    Outsourced Pharma brought together a panel of experts at sponsor companies to discuss specifically how small biopharma can compete for attention at CDMOs.

42. Sponsors And Providers Reaching Financial Summits 3/1/2019

    Tim Scott, founder and CEO at both a CDMO and start-up biotech, maps out financial understanding for leaders of both approaches.

43. A Biotech's Guide To Selecting CDMOs: “35 Or 6 To 2” 3/1/2019

    How one biotech started with a list of 35 possible CDMOs and whittled that list down to two.

44. BeiGene Exec Talks Candidly About Quality, Compliance, And Outsourcing 2/1/2019

    Outsourced Pharma Chief Editor Louis Garguilo continues his coverage of the current state of China pharma manufacturing by interviewing Diana Francis, VP of quality and compliance for BeiGene.

45. Biopharma Supply Chains At Industry 4.0 12/3/2018

    To get to a full digital dialogue that includes everything from AI to blockchain to machine learning, drug sponsors and CDMOs alike will need to muster their resources to usher in what the rest of the world already calls Industry 4.0.

46. Quality Adds Empathy To Outsourcing 3/7/2018

    Vinita Kumar, VP of quality at Versartis, talks about how her philosophy on CMO collaboration has been field-tested. “Never does that importance of real collaboration reveal itself more than in hard times for your program when you need it most,” she says.

47. Lucky Seven For Winning CDMOs — And Their Sponsors 3/7/2018

    Outsourced Pharma Chief Editor Louis Garguilo talks about what makes this seventh edition of the Life Science Leader CMO Leadership Awards different from the previous years.

48. How Some Sponsors Internally Evaluate Their CDMOs 3/7/2018

    A panel of supply chain experts share best practices and perspectives on what parameters to use in evaluating CMOs/CDMOs, how to address low performance partners, and how to meet growing FDA expectations.

49. Virtual And Variable: Two Visions For Biopharma Outsourcing In 2018 12/7/2017

    Deborah Dunsire, CEO of XTuit Pharmaceuticals; and Robert Discordia, executive director, global product development & supply procurement for Bristol-Myers Squibb discuss new approaches to external partnerships in pharma.

50. Boehringer Ingelheim And The Two Sides Of Biologics Outsourcing 9/28/2017

    Jens Vogel, President & CEO, BI Fremont Inc., can’t help seeing two sides to most everything associated with the development and manufacturing of biologics. For example, he says we are in an era that at the same time can be dubbed “Death of the Blockbuster” and “Return of the Blockbuster.”